Clinical Trial

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 9, 2023 (before its estimated September 30, 2023 completion). Its status may not reflect the trial's current state.
Summary
This is a signle-arm, multi-center, open-lable, phase II study. The objective is to evaluate the effectiveness and safety of tislelizumab + oxaliplatin + capecitabine + PLD in the neoadjuvant treatment of resectable gastric adenocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-09-07.
Trial Details
NCT Number NCT05536102
Lead Sponsor Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions Gastric Cancer
Enrollment 38 participants
Start Date 2022-09-05
Primary Completion 2023-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-03-09